Natco Pharma shares! Q3 declines 20% as a result of lower in income – INA NEWS

Natco Pharma Inventory Value: On February 13, Natco Pharma shares fell by about 20 % and the value on BSE touched a low of Rs 975. The decrease circuit is at Rs 973.35. The corporate is getting big promoting within the inventory as a result of declining about 38 % on an annual foundation within the October-December 2024 quarter. The corporate’s internet consolidated revenue was Rs 132.4 crore in the course of the quarter. It was Rs 212.7 crore a yr in the past.

Income from the corporate’s operations on the consolidated foundation fell by 37.4 % to Rs 474.8 crore than a yr in the past. The income within the December 2023 quarter was Rs 758.6 crore. The expenditure declined to Rs 487.4 crore, which was value Rs 539.3 crore a yr in the past.

25 % damaged in every week Natco pharma

After recent promoting, the market cap of Natco Pharma has come all the way down to Rs 17,600 crore. The corporate’s inventory has seen a 16 % rise within the final one yr. On the identical time, the inventory has come down 25 % in only one week. The corporate had a 49.62 % stake within the firm until the top of December 2024.

Kotak Mahindra Financial institution’s share jumped 2% because of the elimination of RBI ban, brokerage said- Reretting could also be

Saleing couldn’t cease even the announcement of dividend

In keeping with data given to the inventory markets, the board of Natco Pharma has declared the third interim dividend of Rs 1.50 per share for FY 2024-25. The report date for this has been mounted at 18 February 2025. By this date, shareholders whose names might be within the data of the Register of Members of the Firm or Depositors because the beneficiaries homeowners of shares might be entitled to dividend. Dividend’s cost will begin from 28 February 2025. Natco Pharma share face worth is Rs 2.

Voda Thought Share Value: Dot requested for a financial institution assure of ₹ 6090 crore, but as a result of this, the shares jumped 4%

The corporate has additionally informed the inventory markets that Dr. Navan Ganpati Bhat has resigned by Dr. Navan Ganpati Bhat, Director and Government Vice President (Technical Operations) of Natco Pharma. It’s efficient since 12 February 2025. Bhat has resigned to search out new alternatives exterior the corporate.

Disclaimer: Right here data supplied is being given just for data. It’s essential to say right here that the funding market available in the market is topic to dangers. At all times seek the advice of specialists earlier than investing cash as an investor. There’s by no means recommendation to anybody to take a position cash on behalf of Moneycontrol.